نتائج البحث

Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.

• Authors : Funk RS; Department of Pharmacy Practice, The University of Kansas Medical Center, 3901 Rainbow Blvd, MS 4047, Rm 6013, Kansas City, KS, 66160, USA. .; Shakhnovich V

Subjects: Arthritis, Juvenile*/Arthritis, Juvenile*/Arthritis, Juvenile*/blood ; Arthritis, Juvenile*/Arthritis, Juvenile*/Arthritis, Juvenile*/diagnosis ; Arthritis, Juvenile*/Arthritis, Juvenile*/Arthritis, Juvenile*/drug therapy

• Source: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2021 May 01; Vol. 19 (1), pp. 62. Date of Electronic Publication: 2021 May 01.Publisher: BioMed Central Country of Publication: England NLM ID: 101248897 Publication Model: Electronic Cited Medium: Internet ISSN: 1546-0096

تفاصيل العنوان

Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet's Uveitis: Customizing Therapy according to the Clinical Features.

• Authors : De Simone L; Ocular Immunology Unit, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.; Invernizzi A

Subjects: Behcet Syndrome*/Behcet Syndrome*/Behcet Syndrome*/diagnosis ; Behcet Syndrome*/Behcet Syndrome*/Behcet Syndrome*/drug therapy ; Uveitis*/Uveitis*/Uveitis*/chemically induced

• Source: Ocular immunology and inflammation [Ocul Immunol Inflamm] 2022 Feb 17; Vol. 30 (2), pp. 506-514. Date of Electronic Publication: 2020 Oct 06.Publisher: Informa Healthcare Country of Publication: England NLM ID: 9312169 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy.

• Authors : Köse HC; Department of Ophthalmology, Ankara University Faculty of Medicine, Mamak, Ankara, Turkey.; Yalçındağ N

Subjects: Behcet Syndrome*/Behcet Syndrome*/Behcet Syndrome*/diagnosis ; Behcet Syndrome*/Behcet Syndrome*/Behcet Syndrome*/drug therapy ; Uveitis*/Uveitis*/Uveitis*/diagnosis

• Source: Ocular immunology and inflammation [Ocul Immunol Inflamm] 2022 Jan 02; Vol. 30 (1), pp. 203-207. Date of Electronic Publication: 2020 Aug 11.Publisher: Informa Healthcare Country of Publication: England NLM ID: 9312169 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Early versus late initiation of infliximab for refractory uveitis in a cohort of Egyptian BD patients.

• Authors : Fadel, Mariam R.¹ (AUTHOR); AboulNaga, Shereen H.¹ (AUTHOR); ElGhobashy, Nehal² (AUTHOR)

• Source: Journal of the Egyptian Ophthalmological Society. Jul-Sep2024, Vol. 117 Issue 3, p193-201. 9p.

تفاصيل العنوان

A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.

• Authors : Horiguchi N; Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.; Department of Ophthalmology, Nagano Prefectural Federation of Agricultural Cooperatives for Health and Welfare, Saku General Hospital, Nagano, Japan.

Subjects: Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Behcet Syndrome/Behcet Syndrome/Behcet Syndrome/*drug therapy ; Infliximab/Infliximab/Infliximab/*therapeutic use

• Source: Scientific reports [Sci Rep] 2020 Dec 17; Vol. 10 (1), pp. 22227. Date of Electronic Publication: 2020 Dec 17.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet's Disease †.

• Authors : Barroso-García, Nuria¹ (AUTHOR) ; Martín-Varillas, José Luis^2,3 (AUTHOR) ; Ferraz-Amaro, Iván⁴ (AUTHOR)

• Source: Journal of Clinical Medicine. Dec2024, Vol. 13 Issue 23, p7388. 12p.

تفاصيل العنوان

Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis.

• Authors : Miraldi Utz V; Abrahamson Pediatric Eye Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. .; Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA. .

Subjects: Medication Adherence*; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Infliximab/Infliximab/Infliximab/*therapeutic use

• Source: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2019 Nov 29; Vol. 17 (1), pp. 79. Date of Electronic Publication: 2019 Nov 29.Publisher: BioMed Central Country of Publication: England NLM ID: 101248897 Publication Model: Electronic Cited Medium: Internet ISSN: 1546-0096

تفاصيل العنوان

Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.

• Authors : Fabiani C; a Department of Ophthalmology , Humanitas Clinical and Research Center , Rozzano (Milan) , Italy.; Sota J

Subjects: Forecasting* ; Visual Acuity*; Behcet Syndrome/Behcet Syndrome/Behcet Syndrome/*drug therapy

• Source: Ocular immunology and inflammation [Ocul Immunol Inflamm] 2019; Vol. 27 (1), pp. 34-39. Date of Electronic Publication: 2017 Nov 03.Publisher: Informa Healthcare Country of Publication: England NLM ID: 9312169 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Response to the Second TNF-α Inhibitor (Adalimumab or Infliximab) after Failing the First One in Refractory Idiopathic Inflammatory Retinal Vascular Leakage.

• Authors : Maleki, Arash^1,2 (AUTHOR); Garcia, Cristina M^1,2 (AUTHOR); Asgari, Soheila³ (AUTHOR)

• Source: Ocular Immunology & Inflammation. Jul2022, Vol. 30 Issue 5, p1099-1108. 10p.

تفاصيل العنوان

INFLIXIMAB and ADALIMUMAB in Uveitic Macular Edema.

• Authors : Lejoyeux R; a Ophthalmology Department, Reference Center for Rare Diseases OPTHARA, Pitié-Salpétrière Hospital , Paris VI University , Paris , France.; Diwo E

Subjects: Adalimumab/Adalimumab/Adalimumab/*therapeutic use ; Anti-Inflammatory Agents/Anti-Inflammatory Agents/Anti-Inflammatory Agents/*therapeutic use ; Infliximab/Infliximab/Infliximab/*therapeutic use

• Source: Ocular immunology and inflammation [Ocul Immunol Inflamm] 2018; Vol. 26 (7), pp. 991-996. Date of Electronic Publication: 2018 Aug 10.Publisher: Informa Healthcare Country of Publication: England NLM ID: 9312169 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان